Century Therapeutics, Inc. (IPSC) Misses Q4 EPS by 168c

Century Therapeutics, Inc. (NASDAQ: IPSC) reported Q4 EPS of ($2.27), $1.68 worse than the analyst estimate of ($0.59). Revenue for the quarter came in at $5.2 million versus the consensus estimate of $2.27 million.

For earnings history and earnings-related data on Century Therapeutics, Inc. (IPSC) click here.

You May Also Be Interested In

• PG&E downgraded by Wells Fargo, BMO as California wildfire reform falls short
• BofA turns S&P 500 signals from red to yellow: What to buy now
• Ulta Beauty (ULTA) Tops Q2 EPS by 38c, Offers Outlook